Zacks Investment Research Lowers OptiNose (NASDAQ:OPTN) to Hold

Share on StockTwits

Zacks Investment Research cut shares of OptiNose (NASDAQ:OPTN) from a buy rating to a hold rating in a research report sent to investors on Thursday morning, Zacks.com reports.

According to Zacks, “OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company’s lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. “

Several other equities research analysts have also recently weighed in on the stock. Cantor Fitzgerald restated a buy rating and issued a $27.00 price target on shares of Spero Therapeutics in a research report on Thursday, May 9th. Piper Jaffray Companies set a $29.00 price target on shares of OptiNose and gave the stock a buy rating in a research report on Tuesday, April 23rd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. OptiNose currently has an average rating of Buy and a consensus target price of $23.30.

OPTN stock opened at $8.00 on Thursday. OptiNose has a one year low of $5.66 and a one year high of $28.04. The stock has a fifty day moving average of $7.22. The company has a current ratio of 6.95, a quick ratio of 6.74 and a debt-to-equity ratio of 0.79.

OptiNose (NASDAQ:OPTN) last released its earnings results on Thursday, May 9th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.01. OptiNose had a negative net margin of 983.22% and a negative return on equity of 81.04%. The firm had revenue of $4.48 million for the quarter, compared to the consensus estimate of $4.35 million. On average, equities research analysts predict that OptiNose will post -2.97 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. RTW Investments LP bought a new stake in OptiNose in the fourth quarter worth $493,000. Two Sigma Advisers LP bought a new stake in OptiNose in the fourth quarter worth $135,000. American Century Companies Inc. increased its position in OptiNose by 19.1% in the fourth quarter. American Century Companies Inc. now owns 242,616 shares of the company’s stock worth $1,504,000 after purchasing an additional 38,842 shares during the last quarter. JPMorgan Chase & Co. increased its position in OptiNose by 8.1% in the first quarter. JPMorgan Chase & Co. now owns 2,503,969 shares of the company’s stock worth $25,791,000 after purchasing an additional 187,174 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in OptiNose in the fourth quarter worth $646,000. Institutional investors own 63.68% of the company’s stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Recommended Story: Strangles

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.